The study population had a mean age of 54 years and a mean BMI of 36.1 kg/m 2 and experienced a BW reduction of 12.8%, 14.7% and 3.2% with tirzepatide 10 mg, tirzepatide 15 mg and placebo, respectively, at 72 weeks 37
nausea, diarrhea, constipation, and mild stomach discomfort typically more pronounced during dose escalation and tending to lessen with time
Most patients notice increased energy within a day or two, with continued benefits over time
It accelerates tendon fibroblast outgrowth, increases cell survival under stress, and promotes cell migration, likely through the activation of the FAK-paxillin pathway
Special population studies Investigating cagrilintide in populations with specific metabolic conditions, different ethnic backgrounds, and varying baseline characteristics
Combining GHK-Cu with treatments like microneedling, as directed by a provider, may enhance results